Metabolic Barriers to T Cell Function in Tumors
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
The metabolic programs that drive T cell functions are exquisitely sensitive to cell intrinsic and extrinsic factors, allowing T cells to respond in a fine-tuned manner to a variety of immune challenges and conditions. However, many of the factors essential for effector T cell function are perturbed in the tumor microenvironment, where oncogenic mutations drive unrestrained cancer cell growth that leads to excess nutrient consumption, excess waste excretion, and insufficient oxygen delivery. This imposes metabolic constraints on infiltrating cells that result in dysfunction and loss of potential antitumor activity in both naturally occurring as well as tailored T cells introduced as part of immunotherapy. In this review, we highlight the metabolic properties that characterize tumor-infiltrating T cells, the barriers within the metabolic landscape of the tumor microenvironment, and the opportunities and challenges they present in development of new cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is known that mesothelioma cells increase the expression of L-type Amino acid Transporter 1 (LAT1), depriving T-cells of amino acids, such as arginine and tryptophan, which are essential for T-cell function and proliferation [121].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mesothelioma cells could also inhibit T-cell glycolysis and functions, increasing the levels of indoleamine-pyrrole 2,3-dioxygenase (IDO), which degrades tryptophan into kynurenine, a well-known immunosuppression factor [121,123,124].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the mesothelioma microenvironment, the availability of glucose is critical, and competition for this molecule impacts on T-cell function and the recruitment of immune infiltrating cells, promoting angiogenesis [119,120,121,122].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [121]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“required for maintaining the TCA cycle as well as a vital source for lipid synthesis through reductive carboxylation in hypoxic cancer cells (1) and Teff cells (2).”
BackgroundCommensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“Both in vitro and in vivo studies in the gut suggest short chain FAs can induce Treg cell differentiation (67, 68), although this may be through changes in G protein–coupled receptor-mediated signaling rather than direct use as a metabolic fuel.”
BackgroundThe Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413 · cited 1×
“Both in vitro and in vivo studies in the gut suggest short chain FAs can induce Treg cell differentiation (67, 68), although this may be through changes in G protein–coupled receptor-mediated signaling rather than direct use as a metabolic fuel.”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Consider PD-1 blockade, which has yielded promising results in many cancer patients, but not so in a sizeable population of patients (83).”
BackgroundKim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 1×
“Increased HIF1a activity promotes aerobic glycolysis and reduces OXPHOS by upregulating pyruvate dehydrogenase kinase (PDK1) and lactate dehydrogenase A (26, 27), effectively shunting pyruvate away”
BackgroundMetabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.016 · Cited by 3,331
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172 · cited 1×
“Hypoxia and upregulation of HIF1a in tumors are both associated with poor clinical outcomes in cancer patients (69).”
BackgroundFunctional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046 · cited 1×
“Additionally, lactate has been shown to stabilize HIF1a in macrophages (74), and can be predicted to have similar effects in T cells.”
BackgroundIschaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907
Understanding the Intersections between Metabolism and Cancer Biology
Vander Heiden, M. G., & DeBerardinis, R. J. (2017) · Cell · doi:10.1016/j.cell.2016.12.039 · Cited by 2,293
Research works printed but not linked: 3
- Michalek RD Gerriets VA Jacobs SR Macintyre AN MacIver NJ Mason EF Sullivan SA Nichols AG Rathmell JC 2011 Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets The Journal of Immunology 186 3299 3303 21317389 PMC3198034
- Gerriets VA Kishton RJ Johnson MO Cohen S Siska PJ Nichols AG Warmoes MO de Cubas AA MacIver NJ Locasale JW Turka LA Wells AD Rathmell JC 2016 Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression Nat Immunol 17 1459 1466 27695003 PMC5215903
- Frauwirth KA Riley JL Harris MH Parry RV Rathmell JC Plas DR Elstrom RL June CH Thompson CB 2002 The CD28 Signaling Pathway Regulates Glucose Metabolism Immunity 16 769 777 12121659
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity
Ringel, A. E., Drijvers, J. M., Baker, G. J., Catozzi, A., García-Cañaveras, J. C., Gassaway, B. M., Miller, B. C., Juneja, V. R., Nguyen, T. H., Joshi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.009 · Cited by 780
“Tumor cell metabolism is known to alter many aspects of the local metabolic landscape in ways that inhibit anti-tumor immunity (Sugiura and Rathmell, 2018).”
BackgroundMetabolites and the Tumour Microenvironment: From Cellular Mechanisms to Systemic Metabolism
Elia, I., & Haigis, M. C. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00317-z · Cited by 651
Metabolic barriers to cancer immunotherapy
DePeaux, K., & Delgoffe, G. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00541-y · Cited by 597
Metabolic and epigenetic regulation of T-cell exhaustion
Franco, F., Jaccard, A., Romero, P., Yu, Y.-R., & Ho, P.-C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00280-9 · Cited by 455
T Cell Dysfunction and Exhaustion in Cancer
Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00017 · Cited by 385
“However, activated and functional CD8+ T cells can also overexpress PD-1 in cancer patients (Fourcade et al., 2010), and not all PD-1+ cells might respond equally to anti-PD-1 therapy (Thommen et al., 2018).”
BackgroundHornburg, M., Desbois, M., Lu, S., Guan, Y., Lo, A. A., Kaufman, S., Elrod, A., Lotstein, A., DesRochers, T. M., Munoz-Rodriguez, J. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.004 · Cited by 383
Elia, I., Rowe, J. H., Johnson, S., Joshi, S., Notarangelo, G., Kurmi, K., Weiss, S., Freeman, G. J., Sharpe, A. H., & Haigis, M. C. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.008 · Cited by 351
Tumour burden and efficacy of immune-checkpoint inhibitors
Dall’Olio, F. G., Marabelle, A., Caramella, C., Garcia, C., Aldea, M., Chaput, N., Robert, C., & Besse, B. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00564-3 · Cited by 350
Immunometabolic Interplay in the Tumor Microenvironment
Kaymak, I., Williams, K. S., Cantor, J. R., & Jones, R. G. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.09.004 · Cited by 328
“, proteins, nucleotides, lipids) and cellular redox homeostasis (Cantor and Sabatini, 2012; Kong and Chandel, 2018; O’Sullivan et al., 2019; Pearce et al., 2013; Sugiura and Rathmell, 2018).”
BackgroundMitochondrial fragmentation limits NK cell-based tumor immunosurveillance
Zheng, X., Qian, Y., Fu, B., Jiao, D., Jiang, Y., Chen, P., Shen, Y., Zhang, H., Sun, R., Tian, Z., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0511-1 · Cited by 316
Ferroptosis in the tumor microenvironment: perspectives for immunotherapy
Xu, H., Ye, D., Ren, M., Zhang, H., & Bi, F. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.014 · Cited by 294
The Tumor Metabolic Microenvironment: Lessons from Lactate
García-Cañaveras, J. C., Chen, L., & Rabinowitz, J. D. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3726 · Cited by 243
Comito, G., Iscaro, A., Bacci, M., Morandi, A., Ippolito, L., Parri, M., Montagnani, I., Raspollini, M. R., Serni, S., Simeoni, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0688-7 · Cited by 241
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Hu, B., Yu, M., Ma, X., Sun, J., Liu, C., Wang, C., Wu, S., Fu, P., Yang, Z., He, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1022 · Cited by 211
Daei Sorkhabi, A., Mohamed Khosroshahi, L., Sarkesh, A., Mardi, A., Aghebati-Maleki, A., Aghebati-Maleki, L., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 208
“Furthermore, excessive aerobic glycolysis of tumor cells increases the synthesis of lactate, an immunosuppressive metabolite in TME (212).”
BackgroundMetabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity
Shi, H., & Chi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02716 · Cited by 202
“This metabolic shift in cancer cells leads to the consumption of environmental glucose and glutamine, thus leading local T cells to adopt unresponsive or functionally exhausted states (205, 206).”
BackgroundTargeting Cancer Stem Cells in Triple-Negative Breast Cancer
Park, S.-Y., Choi, J.-H., & Nam, J.-S. (2019) · Cancers · doi:10.3390/cancers11070965 · Cited by 192
“Furthermore, high rates of tumor glycolysis limit the availability of glucose for tumor-infiltrating lymphocytes, which require sufficient glucose for their effector functions, and impair T cell trafficking and T cell cytotoxicity [125,126].”
BackgroundValle-Casuso, J. C., Angin, M., Volant, S., Passaes, C., Monceaux, V., Mikhailova, A., Bourdic, K., Avettand-Fenoel, V., Boufassa, F., Sitbon, M., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.015 · Cited by 191
Pharmacologic Screening Identifies Metabolic Vulnerabilities of CD8+ T Cells
Drijvers, J. M., Gillis, J. E., Muijlwijk, T., Nguyen, T. H., Gaudiano, E. F., Harris, I. S., LaFleur, M. W., Ringel, A. E., Yao, C.-H., Kurmi, K., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0384 · Cited by 191
“The combination of high metabolic activity of cells in the TME and limited blood supply to the tumor may result in a scarcity of important nutrients and oxygen, which cancer cells and immune cells then compete for (12, 14, 15).”
BackgroundModulation of regulatory T cell function and stability by co-inhibitory receptors
Lucca, L. E., & Dominguez-Villar, M. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0296-3 · Cited by 189
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
Verdura, S., Cuyàs, E., Cortada, È., Brunet, J., López‐Bonet, E., Martín-Castillo, B., Bosch‐Barrera, J., Encinar, J. A., & Menéndez, J. A. (2020) · Aging · doi:10.18632/aging.102646 · Cited by 167
Ferroptosis: a double-edged sword mediating immune tolerance of cancer
Dang, Q., Sun, Z., Wang, Y., Wang, L., Liu, Z., & Han, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05384-6 · Cited by 165
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
“According to Sugiura et al., immune-desert tumors employ metabolic adaptations against efficient T cell functionality and proliferation [282].”
BackgroundBrown, Z. J., Fu, Q., Ma, C., Kruhlak, M., Zhang, H., Luo, J., Heinrich, B., Yu, S. J., Zhang, Q., Wilson, A., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0687-6 · Cited by 143
Miller, K. D., O’Connor, S., Pniewski, K. A., Kannan, T., Acosta, R., Mirji, G., Papp, S. B., Hulse, M., Mukha, D., Hlavaty, S. I., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00636-6 · Cited by 150
“Our current findings suggest that acetate is used by CD8 + T cells and NK cells when glucose availability is low or competition between cancer cells and stromal cells for nutrients is challenging, such as often occurs in the harsh tumor microenvironment 56,57 .”
BackgroundRecent updates on cancer immunotherapy
Liu, M., & Guo, F. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby011 · Cited by 145
“IL-2 has been approved by the FDA for treatment of metastatic renal cell carcinoma (RCC) and metastatic melanoma.21 IL-2 combined with EGFR TKI gefitinib has shown improved outcome in patients with advanced non-small-cell lung cancer (NSCLC).22 IL-2 is used to expand autologous tumor infiltrating lymphocytes (TIL), ly…”
BackgroundInfluentialPD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?
Khasraw, M., Reardon, D. A., Weller, M., & Sampson, J. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1135 · Cited by 143
“Lactate production, presence of an acidic TME, and lipogenesis may alter the immunometabolism of T cells, affecting TCR engagement, T effector activation, differentiation, and proliferation, ultimately resulting in reduction or absence of TILs (30, 36).”
BackgroundInfluentialGLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency
Guerrero, J. A., Klysz, D. D., Chen, Y., Malipatlolla, M. B., Lone, J. B., Fowler, C., Stuani, L., May, A., Bashti, M., Xu, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52666-y · Cited by 132
“Like non-engineered T cells, CAR-T cells must sustain the metabolic and energetic needs required for activation, proliferation, differentiation, and killing by balancing glycolysis and oxidative phosphorylation (OXPHOS) 19,20 while competing with tumor cells for nutrients 21 – 23 .”
BackgroundYao, C.-C., Sun, R.-M., Yang, Y., Zhou, H., Meng, Z., Chi, R., Xia, L., Ji, P., Chen, Y., Zhang, G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112186 · Cited by 112
Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
Verdura, S., Cuyàs, E., Martin-Castillo, B., & Menendez, J. A. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1633235 · Cited by 98
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 99
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 89
“274 Exhausted T cells exhibit impaired mitochondrial respiration and glycolysis, 275,276 and this metabolic reprogramming critically in fl uences energy availability and T cell functionality.”
Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors
Donnadieu, E., Dupré, L., Pinho, L. G., & Cotta-de-Almeida, V. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mr0520-746r · Cited by 87
A Metabolism Toolbox for CAR T Therapy
Xu, X., Gnanaprakasam, J. N. R., Sherman, J., & Wang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00322 · Cited by 83
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
Munn, D. H., Sharma, M. D., & Johnson, T. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1351 · Cited by 84
“Unlike effector T cells, Tregs are tolerant of low glucose, and glucose deprivation appears to actively promote Treg suppressive function (53).”
BackgroundLópez, E., Karattil, R., Nannini, F., Cheung, G. W.-K., Denzler, L., Gálvez‐Cancino, F., Quezada, S. A., & Pulè, M. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006287 · Cited by 82
UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling
Dikshit, A., Jin, Y. J., Degan, S., Hwang, J., Foster, M. W., Li, C., & Zhang, J. Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1040 · Cited by 80
“Further studies are needed to understand 398 how UBE2N regulates the metabolic landscape of the tumor microenvironment which by 399 itself provides a goldmine of opportunities for new cancer therapeutics (42).”
BackgroundTGF-β in Cancer: Metabolic Driver of the Tolerogenic Crosstalk in the Tumor Microenvironment
Angioni, R., Sánchez‐Rodríguez, R., Viola, A., & Molon, B. (2021) · Cancers · doi:10.3390/cancers13030401 · Cited by 78
“In particular, the increased activity of the Indeolamine-2,3-dioxygenase (IDO), converting tryptophan to kyneurinine, has been described in different human cancer, including melanoma and ovarian cancer [148].”
BackgroundKing, R. J., Shukla, S. K., He, C., Vernucci, E., Thakur, R., Attri, K. S., Dasgupta, A., Chaika, N. V., Mulder, S. E., Abrego, J., et al. (2022) · Oncogene · doi:10.1038/s41388-021-02132-6 · Cited by 75
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
“LAT1 transports both arginine and tryptophan and therefore the tumor can deprive T-cells of amino acids essential for T-cell proliferation and function (64).”
BackgroundTargeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response
Chatterjee, S., Chakraborty, P., Daenthanasanmak, A., Iamsawat, S., Andrejeva, G., Luevano, L. A., Wolf, M., Baliga, U., Krieg, C., Beeson, C. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0706 · Cited by 64
“Clin Cancer Res; 25(3) February 1, 2019 Clinical Cancer Research 1040”
BackgroundInfluentialSelf-citationNIX-Mediated Mitophagy Promotes Effector Memory Formation in Antigen-Specific CD8+ T Cells
Gupta, S. S., Sharp, R., Hofferek, C. J., Kuai, L., Dorn, G. W., Wang, J., & Chen, M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.032 · Cited by 61
“FASN participates in the synthesis of long-chain fatty acids, which memory CD8 + T cells depend upon for their metabolism (O’Sullivan et al., 2014; Sugiura and Rathmell, 2018).”
Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance
Muraoka, D., Harada, N., Shiku, H., & Akiyoshi, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.004 · Cited by 56
Metabolic determinants of lupus pathogenesis
Teng, X., Brown, J., Choi, S., Li, W., & Morel, L. M. (2020) · Immunological Reviews · doi:10.1111/imr.12847 · Cited by 55
Predator-Prey in Tumor-Immune Interactions: A Wrong Model or Just an Incomplete One?
Kareva, I., Luddy, K. A., O’Farrelly, C., Gatenby, R. A., & Brown, J. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.668221 · Cited by 54
Salmon, A. J., Shavkunov, A. S., Miao, Q., Jarjour, N. N., Keshari, S., Esaulova, E., Williams, C. D., Ward, J. P., Highsmith, A. M., Pineda, J. E., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0129 · Cited by 51
“:3) ve and memory T cells rely on OXPHOS as the primary energy source, T eff cells additionally require aerobic glycolysis (44, 45).”
Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy
Li, H., Zhao, A., Li, M., Shi, L., Han, Q., & Hou, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1046755 · Cited by 50
“In the TME, the high metabolic activity of cancer cells and limited blood supply contribute to the scarcity of important nutrients and oxygen, causing tumor cells and immune cells, which have similar metabolic demands, to compete for nutrients and oxygen (26).”
BackgroundMRI techniques for immunotherapy monitoring
Lau, D., Corrie, P. G., & Gallagher, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004708 · Cited by 49
Manipulating T-cell metabolism to enhance immunotherapy in solid tumor
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1090429 · Cited by 49
“Glutamine can support OXPHOS via the TCA cycle (48).”
BackgroundLymph nodes: at the intersection of cancer treatment and progression
Reticker-Flynn, N. E., & Engleman, E. G. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.04.001 · Cited by 47
Ong, S. T., Ng, A. S., Ng, X. R., Zhuang, Z., Wong, B. H. S., Prasannan, P., Kok, Y. J., Bi, X., Shim, H., Wulff, H., et al. (2019) · Bioelectricity · doi:10.1089/bioe.2019.0016 · Cited by 47
Mitochondrial complex II in intestinal epithelial cells regulates T cell-mediated immunopathology
Fujiwara, H., Seike, K., Brooks, M. D., Mathew, A. V., Kovalenko, I., Pal, A., Lee, H., Peltier, D., Kim, S. H., Liu, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01048-3 · Cited by 47
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 46
“Tumor growth can lead to a decrease in oxygen perfusion and result in a hypoxic TME, a signature of advanced cancer [255].”
InfluentialChen, Z., Zhu, Z., Hu, T., Yao, C., & Wu, T. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01378-4 · Cited by 44
“In parallel, glycolytic fl ux is suppressed through both extrinsic and intrinsic mechanisms [137, 185, 187].”
Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1988509 · Cited by 43
“In the hostile TME, the uncontrolled growth of malignant cells results in unbalance or aberrant levels of metabolites and oxygen [39].”
BackgroundInfluentialHow metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
Acker, H. H. V., Ma, S., Scolaro, T., Kaech, S. M., & Mazzone, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.006 · Cited by 41
Liu, L., Huang, X., Xu, C., Chen, C., Zhao, W., Li, D., Li, L., Wang, L., & Du, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02371-3 · Cited by 40
Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes
Nanjireddy, P., Olejniczak, S. H., & Buxbaum, N. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121565 · Cited by 40
“Glutamine is a major anaplerotic fuel required for maintaining the TCA cycle (40) and reductive carboxylation in effector T cells (41, 42).”
BackgroundFiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Lipid metabolic reprogramming in colorectal cancer: mechanisms and therapeutic strategies
Liu, W., Dong, S., Hao, F., Gao, Y., & Wei, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603032 · Cited by 39
“…(107); linoleic acid increases CPT1A in CD4+ T cells, the expression of cell markers (114). leading to oxidative stress and inducing apoptosis (108); linoleic In the tumor microenvironment, innate immune cells mainly acid increases CPT1A in CD4+ T cells, leading to oxidative stress include…”
Saturated fatty acids dampen the immunogenicity of cancer by suppressing STING
Heath, B. R., Gong, W., Taner, H. F., Broses, L. J., Okuyama, K., Cheng, W., Jin, M., Fitzsimonds, Z. R., Manousidaki, A., Wu, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112303 · Cited by 39
“31–35 As the tumors from obese hosts were even more glycolytic, we assessed the effector function of tumor-infil-trating lymphocytes (TILs).”
García‐Cañaveras, J. C., & Lahoz, A. (2021) · Cancers · doi:10.3390/cancers13133230 · Cited by 38
“These combined metabolic interactions may enable cancer cells to cover their metabolic needs and to evade immune surveillance and destruction [18,19].”
BackgroundAgrawal, B. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0241-x · Cited by 36
“concentrations of these nutrients to sustain increased activity [35].”
BackgroundCAR-T cell immunotherapy for ovarian cancer: hushing the silent killer
Nasiri, F., Farrokhi, K., Kozani, P. S., Kancha, M. M., Shokoohi, S. D., & Kozani, P. S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1302307 · Cited by 35
“…domain; TRBA, T-cell-redirecting bispeci fi c antibodies. characteristics of the TME could also impinge on the transmigration capacity of CAR-Ts as fi ndings have indicated that non-restricted outgrowth of tumor cells results in hypoxic conditions in the TME, impairing T cell motility (38).”
BackgroundZhao, J. H., Zhang, Y., Wei, Z., Li, K., Sun, L., Li, D., & Wang, Y. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.120657 · Cited by 35
“First, resource competition, wherein tumor cells monopolize glucose via the Warburg effect, leading to mTORC1 inhibition and functional exhaustion in effector T cells [46].”
Ren, Y., Li, R., Feng, H., Xie, J., Gao, L., Chu, S., Li, Y., Meng, F., & Ning, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985187 · Cited by 35
“Besides, lowactivated and immunosuppressive ascites-derived gd T cells were observed in epithelial ovarian cancer (62), and low metabolism level of T cells can lead to antitumor dysfunction (63).”
BackgroundRegulating the Obesity-Related Tumor Microenvironment to Improve Cancer Immunotherapy
Fang, H., Wu, Y. D., Chen, L., Cao, Z., Deng, Z., Zhao, R., Zhang, L., Yang, Y., Liu, Z., & Chen, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c11159 · Cited by 35
Ding, J. P., Guyette, S., Schrand, B., Geirut, J., Horton, H. M., Guo, G., Delgoffe, G. M., Menk, A. V., Baeuerle, P. A., Hofmeister, R., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2182058 · Cited by 35
“Intratumoral T cells compete with tumor cells for metabolic resources, such as glucose and amino acids, limiting their proliferation and effector functions.(34) TC-210 T cells had a lower (in vitro) ECAR than CAR-T cells, consistent with reduced glycolytic activity.”
BackgroundInteractions between the metabolic reprogramming of liver cancer and tumor microenvironment
Yang, H., Li, J., Niu, Y., Zhou, T., Zhang, P., Liu, Y., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1494788 · Cited by 34
“…shown that CD28 mediates the upregulation of relevant nutrient transporters ’ expression and their translocation to the cell membrane; for example, an increase in monocarboxylate transporter (MCT) expression is observed in order to facilitate the clearance of lactate produced by glycolysis (163).”
Regulatory T Cells in the Tumor Microenvironment
Dadey, R., Workman, C. J., & Vignali, D. A. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_6 · Cited by 34
Tian, H., Wang, G., Wang, Q., Zhang, B., Jiang, G., Li, H., Chai, D., Fang, L., Wang, M., & Zheng, J. (2022) · Cancer Science · doi:10.1111/cas.15261 · Cited by 34
Immune cell metabolism in autoimmunity
Teng, X., Li, W., Cornaby, C., & Morel, L. M. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13277 · Cited by 34
Malone, T., Schäfer, L., Simon, N., Heavey, S., Cuffe, S., Finn, S., Moore, G., & Gately, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107454 · Cited by 33
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
Staniszewska, M., Iking, J., Lückerath, K., Hadaschik, B. A., Herrmann, K., Ferdinandus, J., & Fendler, W. P. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.03.009 · Cited by 33
Evans, J. V., Suman, S., Goruganthu, M., Tchekneva, E. E., Guan, S., Arasada, R. R., Antonucci, A., Piao, L., Ilgisonis, I. S., Bobko, A. A., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad091 · Cited by 34
“As acidosis and hypoxia are harmful for T-cell antitumor activity (55, 56), including adenosine receptor A 2B antagonist in the combination regimen could ameliorate this adverse effect.”
BackgroundHan, L., Yao, S., Cao, S., Mo, G., Li, J., Cao, Y., & Huang, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s212666 · Cited by 33
“Flow cytometry data was acquired from a splenic cell suspension using the following antibodies: CD19-fluorescein isothiocyanate (FITC) (11-0193-82), CD25-phycoerythrin (PE)-cyanine 5 (Cy5) (15-0251-82), CD3-FITC (110031-82), CD4-FITC (11-0041-82), CD69-PE (12-069182), CD28-PE-Cy5 (15-0281-82), CD335-PE (11-335182), an…”
MethodQiu, Y., Xu, Y., Ding, X., Zhao, C., Cheng, H., & Li, G. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003284 · Cited by 32
“Moreover, glycolytic intermediates fuel anabolic pathways such as the pentose phosphate pathway (PPP) and nucleotide biosynthesis, which are essential for biomass accumulation and clonal expansion of proliferating T cells [65,72,73].”
Jia, N., Ganesan, D., Guan, H., Jeong, Y. Y., Han, S., Rajapaksha, G., Nissenbaum, M., Kusnecov, A. W., & Cai, Q. (2024) · Autophagy · doi:10.1080/15548627.2024.2392408 · Cited by 31
Dimeji, I. Y., Abass, K. S., Audu, N. M., & Adekola, S. A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177615 · Cited by 31
Targeting PIM Kinases to Improve the Efficacy of Immunotherapy
Clements, A. N., & Warfel, N. A. (2022) · Cells · doi:10.3390/cells11223700 · Cited by 31
Selective inhibition of mTORC1 in tumor vessels increases antitumor immunity
Wang, S., Raybuck, A. L., Shiuan, E. F., Cho, S. H., Wang, Q., Brantley‐Sieders, D. M., Edwards, D. N., Allaman, M. M., Nathan, J. A., Wilson, K. T., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.139237 · Cited by 31
“Increased perfusion in normalized vessels could also take oxygen and nutrients (e.g., glucose and amino acids) into the tumor microenvironment for optimal T cell activation and effector function (51, 52).”
Molecular insight into T cell exhaustion in hepatocellular carcinoma
Zhu, Y., Tan, H., Wang, J., Zhuang, H., Zhao, H., & Lu, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107161 · Cited by 30
Regulation of immune cell metabolism in health and disease: Special focus on T and B cell subsets
Chakraborty, S., Khamaru, P., & Bhattacharyya, A. (2022) · Cell Biology International · doi:10.1002/cbin.11867 · Cited by 29
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 30
Sen, P., Andrabi, S. B. A., Buchacher, T., Khan, M. M., Ullah, U., Lindeman, T., Alves, M. A., Hinkkanen, V., Kemppainen, E., Dickens, A. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109973 · Cited by 27
Orlandella, R. M., Turbitt, W. J., Gibson, J. T., Boi, S. K., Li, P., Smith, D. L., & Norian, L. A. (2020) · Cancers · doi:10.3390/cancers12102872 · Cited by 27
“This harsh environment can independently impair CD8 T cell responses [8–10], and accumulating evidence suggests that strategies aimed at restricting glycolytic metabolism within tumors may improve anti-tumor immunity and ICI response [11,12], although other studies demonstrate impaired CD8 T cell function with glucose…”
BackgroundLi, M., Jiang, A., Han, H., Chen, M., Wang, B., Cheng, Y., Zhang, H., Wang, X., Dai, W., Yang, W., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c03352 · Cited by 26
Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy
Jenkins, Y. R., Zabkiewicz, J., Ottmann, O. G., & Jones, N. (2021) · Antibodies · doi:10.3390/antib10020017 · Cited by 26
“Such parallels can be drawn between the lymph node microenvironment and TME, whereby lactate inhibits the effector T cell function [20].”
BackgroundKalyanaraman, B. (2022) · The FASEB Journal · doi:10.1096/fj.202101862r · Cited by 25
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers
Leca, J., Fortin, J., & Mak, T. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.013 · Cited by 25
Metabolic and Immunological Subtypes of Esophageal Cancer Reveal Potential Therapeutic Opportunities
King, R. J., Qiu, F., Yu, F., & Singh, P. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.667852 · Cited by 24
“…can exert influence over the tumor microenvironment (Chang et al., 2015; Allard et al., 2017; Gupta et al., 2017; Rivadeneira and Delgoffe, 2018; Sugiura and Rathmell, 2018; Triplett et al., 2018; Chen et al., 2019; Najjar et al., 2019; Ngwa et al., 2019; Thapa and Lee, 2019; Vigano et al.,…”
BackgroundInfluentialTranslating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition
Ecker, C., & Riley, J. L. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.009 · Cited by 23
“Exciting new technologies and conceptual advancements have re-energized the study of the metabolic competition between tumors and the adaptive immune system (Chang et al., 2015; Ho et al., 2015; Sugiura and Rathmell, 2018).”
Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade
Heath, B. R., Michmerhuizen, N. L., Donnelly, C. R., Sansanaphongpricha, K., Sun, D., Brenner, J. C., & Lei, Y. L. (2019) · Journal of Dental Research · doi:10.1177/0022034519864112 · Cited by 23
Angrini, M., Varthaman, A., & Cremer, I. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-44518-8_9 · Cited by 22
Palen, K. A., Zurko, J. C., Johnson, B. D., Hari, P., & Shah, N. N. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.07.015 · Cited by 21
Metabolic and epigenetic orchestration of (CAR) T cell fate and function
Akbari, B., Hosseini, Z., Shahabinejad, P., Ghassemi, S., Mirzaei, H. R., & O’Connor, R. S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215948 · Cited by 22
Metabolism of Immune Cells in the Tumor Microenvironment
Jung, J. G., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_13 · Cited by 20
Metadata
- Authors
- Sugiura, A., & Rathmell, J. C.
- Affiliations
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Rathmell, Jeffrey C
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 400-407
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5777533
- OpenAlex
- W2784164696
- Cited by
- 208
- References
- 89
- Citations by year
- 2026: 22 · 2025: 18 · 2024: 15 · 2023: 30 · 2022: 35 · 2021: 32 · 2020: 29 · 2019: 18 · 2018: 9
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of General Medical Sciences (T32GM007347)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK105550)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- T cell metabolism, tumor microenvironment, tumor-infiltrating T cells, T cell dysfunction, cancer immunotherapy, nutrient consumption, oxygen delivery, oncogenic mutations, cancer therapeutics
- MeSH terms
- Animals, Energy Metabolism, Humans, Immunotherapy, Lymphocyte Activation, Neoplasms, T-Lymphocytes, Lymphocytes, Tumor-Infiltrating, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.